Research shows bimagrumab may prevent muscle and bone loss associated with weight loss medications like Wegovy, offering hope ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

Researchers at Columbia University Irving Medical Center have identified the specific neurons in mice brains that tell them ...

Glucagon-like peptide-1 (GLP-1) is a well-known medication used by physicians to treat Type 2 diabetes. GLP-1 has also become ...

Department of Chemical Engineering, University of Illinois Chicago, Chicago, Illinois 60607, United States Department of Chemical Engineering, University of Illinois Chicago, Chicago, Illinois 60607, ...

Background: Despite their potential, Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have not been well studied in cardiac amyloidosis (CA) as randomized trials on GLP-1 RA have excluded patients ...

Of those, over 215,000 had been prescribed a glucagon-like peptide-1 (GLP-1) agonist receptor — the class of drugs that includes Ozempic, Wegovy, Mounjaro, Zepbound, and others — and 1.7 ...

The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class of drugs called glucagon-like peptide-1 agonists, or GLP-1.

The following is a summary of “Metabolic Effects of Glucagon Stimulations in Type 1 Diabetes and Healthy Controls,” published in the January 2025 issue of Endocrinology by She et al. Researchers ...

Protein degradation–focused Neomorph nabs its third Big Pharma deal of around $1.5 billion in less than a year. In a licensing deal that could reach up to $1.64 billion, AbbVie is teaming up with ...